Investigation into Centessa's Transaction with Lilly for Possible Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy CNTA?
Source: Globenewswire
- Shareholder Compensation Structure: Centessa shareholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share in the transaction with Lilly, indicating a commitment to short-term shareholder returns while raising concerns about long-term value.
- Milestone Payment Conditions: The contingent value rights include three milestone payments of $2.00 for FDA approval of narcolepsy treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030, which may influence the company's future R&D direction.
- Board Responsibility Investigation: Ademi LLP is investigating whether Centessa's board fulfilled its fiduciary duties to all shareholders in light of the significant penalties imposed on competing transactions, which could have legal implications.
- Restrictions on Competing Transactions: The transaction agreement imposes significant penalties on Centessa for accepting competing bids, potentially limiting future market opportunities and negatively impacting shareholder interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to fall
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.600
Low
27.00
Averages
38.75
High
62.00
Current: 39.600
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Dominance in Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, which is expected to solidify the company's leadership in the fast-expanding weight loss market, especially with the recent launch of Foundayo that further broadens its addressable market.
- Diverse Product Portfolio: Beyond Zepbound, Eli Lilly boasts other drugs like Verzenio and Taltz, which generated $5.7 billion and $3.6 billion in sales last year, respectively, showcasing the company's strong growth potential in oncology and immunology, effectively mitigating competitive pressures.
- Strategic Acquisition Plans: Eli Lilly recently acquired Kelonia Therapeutics for $3.25 billion, enhancing its gene therapy platform expected to improve cancer treatment, while also expanding its neuroscience pipeline through the acquisition of Centessa Pharmaceuticals and deepening its oncology pipeline with Scorpion Therapeutics.
- Competitive Market Advantage: Compared to rival Novo Nordisk, Eli Lilly has a clear advantage in product diversity, allowing it to maintain its lead in the weight loss market, and despite facing competition from new drugs, it continues to drive long-term revenue growth.
See More
Eli Lilly's Leadership in the Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, underscoring the company's leadership in the weight loss market, which is expected to drive overall revenue growth and enhance competitive positioning.
- Diverse Product Line: Eli Lilly achieved $5.7 billion in sales for its cancer treatment Verzenio, an 8% year-over-year increase, while immunosuppressant Taltz reached $3.6 billion, demonstrating its strong capabilities across multiple therapeutic areas that help mitigate market competition.
- Strategic Acquisition: Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion grants access to an innovative gene therapy platform, expected to improve cancer treatment outcomes and further strengthen its competitive edge in genetic medicine.
- Future Growth Potential: Analysts expect Eli Lilly's new drugs Ebglyss, Jaypirca, and Kisunla to generate over $1 billion in annual sales, showcasing the company's ongoing innovation and growth potential across various fields.
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Activity: Eli Lilly accelerates its acquisition strategy in 2026 with the buyout of Ajax Therapeutics valued at up to $2.3 billion, including milestone payments, further solidifying its position in blood cancer treatments.
- Drug Development: Ajax's lead drug, AJ1-11095, is a next-generation JAK2 inhibitor currently in Phase 1 trials for patients with Myelofibrosis, aiming to expand treatment options for patients with rare blood cancers.
- Strategic Positioning: This marks Lilly's sixth acquisition this year, including a $6.3 billion deal for Centessa Pharmaceuticals focused on sleep disorders, demonstrating its commitment to deepening its oncology pipeline.
- Market Sentiment: Despite nearly a 20% decline in LLY shares in 2026, retail sentiment on Stocktwits remains bullish, indicating confidence in the company's acquisition strategy and its potential to enhance future growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Centessa Pharmaceuticals plc, KORE Group Holdings, Inc., and Clearwater Analytics Holdings, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders.
- Transaction Details: Centessa Pharmaceuticals is being sold to Eli Lilly for $38.00 per share in cash plus a non-transferrable right worth up to $9.00, KORE Group is selling to Searchlight Capital Partners and Abry Partners for $9.25 per share, while Clearwater Analytics is being sold to Permira and Warburg Pincus for $24.55 per share.
- Shareholder Rights: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, aiming to secure increased consideration and additional disclosures for shareholders involved in these transactions.
- Legal Support: The firm represents investors globally, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, which underscores their expertise in protecting investor rights.
See More
Honeywell Sells Business to Reshape Portfolio Amid Market Uncertainty
- Honeywell Business Sale: Honeywell sells its Productivity Solutions and Services (PSS) business to Brady Corporation for $1.4 billion in cash, a strategic move to divest cyclical, slower-growing, lower-margin operations, thereby enhancing the overall quality of its portfolio.
- Market Reaction Stable: Despite a 5% rise in oil prices due to uncertainty over commercial shipping traffic in the Strait of Hormuz, the market's decline was less severe than feared, as Treasury yields remained relatively unchanged, indicating a stable investor sentiment.
- Eli Lilly Acquisition Moves: Eli Lilly acquires clinical-stage biotech firm Kelonia Therapeutics for $3.25 billion in cash, aiming to bolster its cancer treatment pipeline, with the deal potentially worth up to $7 billion, showcasing the company's aggressive expansion strategy in oncology.
- Active IPO Market: In spite of uncertainties from the Iran conflict, Jersey Mike's confidentially files for an IPO with a valuation of approximately $8 billion, reflecting ongoing interest in new public offerings and further driving growth in investment banking activities.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Merger Investigations: Monteverde Law Firm is investigating the merger between Wintergreen Acquisition Corp. and KIKA Technology Inc., where KIKA shareholders will receive ordinary shares based on valuation, highlighting the firm's commitment to shareholder rights.
- Cash Acquisition Assurance: Centessa Pharmaceuticals shareholders are expected to receive $38 per share in cash along with a contingent value right worth up to $9, indicating the company's dedication to shareholder compensation and potential future gains.
- Shareholder Voting Schedule: Stellar Bancorp shareholders will vote on May 27, 2026, with expectations of receiving 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the importance of transparency and shareholder engagement in merger transactions.
- Tender Offer Deadline: Soleno Therapeutics shareholders are expected to receive $53 per share in cash, with the tender offer expiring on May 15, 2026, emphasizing the urgency for shareholders to act to secure their interests.
See More
Eli Lilly's Dominance in Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, which is expected to solidify the company's leadership in the fast-expanding weight loss market, especially with the recent launch of Foundayo that further broadens its addressable market.
- Diverse Product Portfolio: Beyond Zepbound, Eli Lilly boasts other drugs like Verzenio and Taltz, which generated $5.7 billion and $3.6 billion in sales last year, respectively, showcasing the company's strong growth potential in oncology and immunology, effectively mitigating competitive pressures.
- Strategic Acquisition Plans: Eli Lilly recently acquired Kelonia Therapeutics for $3.25 billion, enhancing its gene therapy platform expected to improve cancer treatment, while also expanding its neuroscience pipeline through the acquisition of Centessa Pharmaceuticals and deepening its oncology pipeline with Scorpion Therapeutics.
- Competitive Market Advantage: Compared to rival Novo Nordisk, Eli Lilly has a clear advantage in product diversity, allowing it to maintain its lead in the weight loss market, and despite facing competition from new drugs, it continues to drive long-term revenue growth.
See More
Eli Lilly's Leadership in the Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, underscoring the company's leadership in the weight loss market, which is expected to drive overall revenue growth and enhance competitive positioning.
- Diverse Product Line: Eli Lilly achieved $5.7 billion in sales for its cancer treatment Verzenio, an 8% year-over-year increase, while immunosuppressant Taltz reached $3.6 billion, demonstrating its strong capabilities across multiple therapeutic areas that help mitigate market competition.
- Strategic Acquisition: Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion grants access to an innovative gene therapy platform, expected to improve cancer treatment outcomes and further strengthen its competitive edge in genetic medicine.
- Future Growth Potential: Analysts expect Eli Lilly's new drugs Ebglyss, Jaypirca, and Kisunla to generate over $1 billion in annual sales, showcasing the company's ongoing innovation and growth potential across various fields.
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Activity: Eli Lilly accelerates its acquisition strategy in 2026 with the buyout of Ajax Therapeutics valued at up to $2.3 billion, including milestone payments, further solidifying its position in blood cancer treatments.
- Drug Development: Ajax's lead drug, AJ1-11095, is a next-generation JAK2 inhibitor currently in Phase 1 trials for patients with Myelofibrosis, aiming to expand treatment options for patients with rare blood cancers.
- Strategic Positioning: This marks Lilly's sixth acquisition this year, including a $6.3 billion deal for Centessa Pharmaceuticals focused on sleep disorders, demonstrating its commitment to deepening its oncology pipeline.
- Market Sentiment: Despite nearly a 20% decline in LLY shares in 2026, retail sentiment on Stocktwits remains bullish, indicating confidence in the company's acquisition strategy and its potential to enhance future growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Centessa Pharmaceuticals plc, KORE Group Holdings, Inc., and Clearwater Analytics Holdings, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders.
- Transaction Details: Centessa Pharmaceuticals is being sold to Eli Lilly for $38.00 per share in cash plus a non-transferrable right worth up to $9.00, KORE Group is selling to Searchlight Capital Partners and Abry Partners for $9.25 per share, while Clearwater Analytics is being sold to Permira and Warburg Pincus for $24.55 per share.
- Shareholder Rights: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, aiming to secure increased consideration and additional disclosures for shareholders involved in these transactions.
- Legal Support: The firm represents investors globally, focusing on securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, which underscores their expertise in protecting investor rights.
See More
Honeywell Sells Business to Reshape Portfolio Amid Market Uncertainty
- Honeywell Business Sale: Honeywell sells its Productivity Solutions and Services (PSS) business to Brady Corporation for $1.4 billion in cash, a strategic move to divest cyclical, slower-growing, lower-margin operations, thereby enhancing the overall quality of its portfolio.
- Market Reaction Stable: Despite a 5% rise in oil prices due to uncertainty over commercial shipping traffic in the Strait of Hormuz, the market's decline was less severe than feared, as Treasury yields remained relatively unchanged, indicating a stable investor sentiment.
- Eli Lilly Acquisition Moves: Eli Lilly acquires clinical-stage biotech firm Kelonia Therapeutics for $3.25 billion in cash, aiming to bolster its cancer treatment pipeline, with the deal potentially worth up to $7 billion, showcasing the company's aggressive expansion strategy in oncology.
- Active IPO Market: In spite of uncertainties from the Iran conflict, Jersey Mike's confidentially files for an IPO with a valuation of approximately $8 billion, reflecting ongoing interest in new public offerings and further driving growth in investment banking activities.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Merger Investigations: Monteverde Law Firm is investigating the merger between Wintergreen Acquisition Corp. and KIKA Technology Inc., where KIKA shareholders will receive ordinary shares based on valuation, highlighting the firm's commitment to shareholder rights.
- Cash Acquisition Assurance: Centessa Pharmaceuticals shareholders are expected to receive $38 per share in cash along with a contingent value right worth up to $9, indicating the company's dedication to shareholder compensation and potential future gains.
- Shareholder Voting Schedule: Stellar Bancorp shareholders will vote on May 27, 2026, with expectations of receiving 0.3803 shares of Prosperity common stock and $11.36 in cash per share, reflecting the importance of transparency and shareholder engagement in merger transactions.
- Tender Offer Deadline: Soleno Therapeutics shareholders are expected to receive $53 per share in cash, with the tender offer expiring on May 15, 2026, emphasizing the urgency for shareholders to act to secure their interests.
See More
